LLY Eli Lilly and Company Loading... : Bullish and Bearish Analyst Opinions
From WST earnings callsLoading chart...
Top Calls
Feed
08:00
Jul 23
Jul 23
Asia Pacific grew 27% organically, driven by generic GLP-1 launches in China and India, plus increasing CDMO work in South Korea. — Generic GLP-1 entrants in emerging markets are adopting West's high-value components, expanding total addressable market beyond branded GLP-1s.
MED
08:00
Feb 12
Feb 12
Management cites Eli Lilly and Novo Nordisk's public commentary that oral GLP-1s are expanding the market rather than cannibalizing injectables, supporting continued demand for West's injectable components.
HIGH
08:00
Oct 23
Oct 23
GLP-1 elastomers now 9% of total sales (vs mid-single-digits in 2024) and growing faster than end-market script data, driven by vial usage, generics, and clinical-trial demand. — West is benefiting disproportionately as GLP‑1 drugmakers expand vial presentations and pipeline molecules, implying higher-than-expected component demand for Lilly and Novo Nordisk.
MED
About LLY Analyst Coverage
Buzzberg tracks LLY (Eli Lilly and Company) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Latest voices: Eric Green.